Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure (Q38200558)

30 August 2017

Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure (English)

1 reference

30 August 2017

0 references

1 reference

Carrie Geisberg Lenneman

series ordinal

1

1 reference

30 August 2017

1 June 2014

1 reference

Current heart failure reports

30 August 2017

1 reference

30 August 2017

11

1 reference

30 August 2017

2

1 reference

30 August 2017

134-138

1 reference

https://scigraph.springernature.com/pub.10.1007/s11897-014-0193-9

30 August 2017

0 references

cites work

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

The role of Neuregulin-1beta/ErbB signaling in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Multiple essential functions of neuregulin in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Requirement for neuregulin receptor erbB2 in neural and cardiac development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Neuregulins: functions, forms, and signaling strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Neuregulin-1 promotes formation of the murine cardiac conduction system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Serum Neuregulin-1beta as a Biomarker of Cardiovascular Fitness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Circulating neuregulin-1β levels vary according to the angiographic severity of coronary artery disease and ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Molecular and cellular mechanisms of anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0193-9

Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24682830

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24682830

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24682830

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11897-014-0193-9

1 reference

PubMed ID

24682830

Dimensions Publication ID

30 August 2017

0 references

1 reference

PubMed ID

24682830